- Home
- IRWD vs ATXS Comparison
IRWD vs ATXS Comparison
Compare IRWD & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- ATXS
- Stock Information
- Founded
- IRWD 1998
- ATXS 2008
- Country
- IRWD United States
- ATXS United States
- Employees
- IRWD N/A
- ATXS N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- IRWD Health Care
- ATXS Health Care
- Exchange
- IRWD Nasdaq
- ATXS Nasdaq
- Market Cap
- IRWD 97.4M
- ATXS 401.2M
- IPO Year
- IRWD 2010
- ATXS 2015
- Fundamental
- Price
- IRWD $0.78
- ATXS $6.59
- Analyst Decision
- IRWD Buy
- ATXS Strong Buy
- Analyst Count
- IRWD 5
- ATXS 7
- Target Price
- IRWD $4.94
- ATXS $32.43
- AVG Volume (30 Days)
- IRWD 2.5M
- ATXS 358.8K
- Earning Date
- IRWD 08-07-2025
- ATXS 08-11-2025
- Dividend Yield
- IRWD N/A
- ATXS N/A
- EPS Growth
- IRWD N/A
- ATXS N/A
- EPS
- IRWD N/A
- ATXS N/A
- Revenue
- IRWD $317,676,000.00
- ATXS N/A
- Revenue This Year
- IRWD N/A
- ATXS N/A
- Revenue Next Year
- IRWD N/A
- ATXS N/A
- P/E Ratio
- IRWD N/A
- ATXS N/A
- Revenue Growth
- IRWD N/A
- ATXS N/A
- 52 Week Low
- IRWD $0.53
- ATXS $3.56
- 52 Week High
- IRWD $7.11
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- IRWD 54.72
- ATXS 69.33
- Support Level
- IRWD $0.70
- ATXS $5.60
- Resistance Level
- IRWD $0.79
- ATXS $5.79
- Average True Range (ATR)
- IRWD 0.06
- ATXS 0.36
- MACD
- IRWD 0.01
- ATXS 0.06
- Stochastic Oscillator
- IRWD 85.59
- ATXS 100.00
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.